Bioxel Pharma received a paclitaxel order valued at $700,000 from a generic manufacturer in the EU. The order will be used in a generic paclitaxel drug currently marketed in Europe. Product deliveries under the order will begin this quarter. “This is the second major paclitaxel order for Bioxel in the past month,” said Pascal Delmas, president and chief executive officer of Bioxel. “We are clearly earning customer confidence and building revenue momentum with a combination...